To evaluate ARL6IP1 gene therapy, we constructed an AAV9 serotype with a chicken β-actin promoter that drives expression in Arl6ip1+/+ mice and estimated its expression in Arl6ip1−/− mice, an HSP model. This evidence concerns the gene ARL6IP1 and hereditary spastic paraplegia.